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Abstract
Background: Mesenchymal stem cells (MSCs) have potent immunomodulatory effects on multiple immune cells and
have great potential in treating immune disorders. Induced pluripotent stem cells (iPSCs) serve as an unlimited and
noninvasive source of MSCs, and iPSC-MSCs have been reported to have more advantages and exhibit immunomodulation
on T lymphocytes and natural killer cells. However, the effects of iPSC-MSCs on dendritic cells (DCs) are unclear. The aim of
this study is to investigate the effects of iPSC-MSCs on the differentiation, maturation, and function of DCs.
Methods: Human monocyte-derived DCs were induced and cultured in the presence or absence of iPSC-MSCs. Flow
cytometry was used to analyze the phenotype and functions of DCs, and enzyme-linked immunosorbent assay (ELISA)
was used to study cytokine production.
Results: In this study, we successfully induced MSCs from different clones of human iPSCs. iPSC-MSCs exhibited a
higher proliferation rate with less cell senescence than BM-MSCs. iPSC-MSCs inhibited the differentiation of human
monocyte-derived DCs by both producing interleukin (IL)-10 and direct cell contact. Furthermore, iPSC-MSCs did not
affect immature DCs to become mature DCs, but modulated their functional properties by increasing their phagocytic
ability and inhibiting their ability to stimulate proliferation of lymphocytes. More importantly, iPSC-MSCs induced the
generation of IL-10-producing regulatory DCs in the process of maturation, which was mostly mediated by a cell-cell
contact mechanism.
Conclusions: Our results indicate an important role for iPSC-MSCs in the modulation of DC differentiation and
function, supporting the clinical application of iPSC-MSCs in DC-mediated immune diseases.
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Background
Mesenchymal stem cells (MSCs) are multipotent cells
that have been shown to have a strong immunomodula-
tory effect on immune diseases via their interaction with
T lymphocytes [1], B lymphocytes [2], natural killer
(NK) cells [3], or dendritic cells (DCs) [4, 5]. MSCs are
generally isolated from bone marrow (BM), adipose tis-
sue, and umbilical cord blood. However, there are sev-
eral potential limitations of using adult MSCs, including
their limited capacity to proliferate, the significant vari-
ability in cell quality derived from different donors, and
the rapid loss of multipotentiality [6, 7]. Induced pluri-
potent stem cells (iPSCs) are the cells that are repro-
grammed from somatic cells using transcription factors
[8]. Similar to embryonic stem cells, iPSCs have been
successfully induced to differentiate into many types of
functional cells, such as neurons [9], cardiocytes [10],
islet cells [11], and also MSCs [12, 13]. iPSCs are
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unspecialized cells that are capable of renewing them-
selves infinitely in a culture dish, which allows them to
serve as an unlimited and noninvasive source of MSCs
[12]. Furthermore, we recently identified that,
compared with adult MSCs, human iPSC-MSCs are
insensitive to proinflammatory interferon (IFN)-γ-in-
duced human leukocyte antigen (HLA)-II expression,
and have a stronger immune privilege after trans-
plantation [14]. However, currently, iPSC-MSCs have
only been reported by a few groups, and most of the iPSCs
used were reprogrammed through genetic transduction
using retroviral or lentiviral vectors [12, 13, 15, 16]. Al-
though iPSC-MSCs exerted good stability and did
not induce any tumor formation [12, 17], the safety
concerns associated with reprogramming using
viruses and the genomic instability of iPSCs still need
to be carefully evaluated, especially for clinical
applications.
We have previously reported that iPSC-MSCs effectively
modulated T-cell phenotypes [18] and inhibited Th2-
dominant allergic airway inflammation [19]. iPSC-MSCs
played a prominent role in the inhibition of the cytolytic
function of NK cells [13]. DCs are the most potent
antigen-presenting cells and are critical for initiating and
regulating immune responses by modulating antigen
(Ag)-specific T-cell activation [20]. In a variety of diseases,
such as allergic asthma and autoimmune diseases, DCs
are necessary and sufficient to induce aberrant immunity
to allergens or self-antigens [21, 22]. Many studies have
reported that human BM-MSCs inhibited DC differ-
entiation and maturation [4, 5, 23, 24] and even in-
duced differentiation of DCs into regulatory DCs
[25–27]. However, the effects of iPSC-MSCs on DCs
are unclear.
In this study, we induced MSCs from two different
clones of human iPSCs, one of which was repro-
grammed by a nonvirus-based approach and without
oncogene c-MYC [28, 29] to show that iPSC-MSCs with
different passages significantly inhibited the differenti-
ation of human DCs from CD14+ monocytes, enhanced
the phagocytosis of mature DCs (mDCs), and induced
the induction of interleukin (IL)-10-producing regulatory
DCs. Furthermore, we found that both cell-cell contact
and IL-10 were responsible for the iPSC-MSC-mediated
inhibition of DC differentiation, whereas only cell-cell
contact was required for the generation of IL-10-
producing DCs with iPSC-MSC treatment in the pro-
gress of DC maturation.
Methods
Preparation of human iPSCs
Two different clones of human iPSCs were used for the
generation of MSCs. Urine cell-derived-iPSCs (U-iPSCs)
were donated by Guangzhou Institute of Biomedicine
and Health, Chinese Academy of Science (Guangzhou,
Guangdong, China) [28]. Amniocyte-derived iPSCs (A-
iPSCs) were commercially purchased from Cell Inspire
Biotechnologies, Inc. (Cat. iPSN-0008; Shenzhen,
Guangdong, China; www.cib.cc). U-iPSCs were repro-
grammed from human urine-derived cells by electropor-
ation with plasmids pEP4EO2SET2K (containing OCT4,
SOX2, SV40LT, and KLF4) [28]. A-iPSCs was generated
from human amniotic fluid cells by transduction with
retrovirus-mediated OCT4, SOX2, KLF4, and c-MYC
factors. Two iPSC clones were maintained on Matrigel
(BD Biosciences, San Jose, NJ, USA) and cultured in
iPSC medium containing mTeSR1 (Stem Cell Technolo-
gies, Vancouver, Canada), 50 U/mL penicillin G and
50 mg/mL streptomycin (Gibco, Invitrogen Corporation,
Carlsbad, CA, USA).
Generation of MSCs from iPSCs
MSCs were generated from iPSCs with a minor modifica-
tion, as described in previous studies [12, 26]. Confluent
flasks of iPSCs were dissociated by ethylenediaminetetra-
acetic acid (EDTA) and then plated onto Matrigel-coated
six-well culture plates. The passaged iPSCs were cultured
in mTeSR1 medium for 2 days until 60% confluency was
achieved. On the third day, mTeSR1 medium was com-
pletely replaced by MSC-inducing culture media with
minimum essential medium Eagle-α modified (α-MEM;
Gibco), 10% serum replacement (Stem Cell Technologies,
Vancouver, Canada), penicillin/streptomycin, sodium pyru-
vate, 50 μML-ascorbate-2-phosphate (Sigma-Aldrich, Inc.,
St. Louis, MO, USA), L-glutamine, and nonessential amino
acids for 2 weeks. Then the heterogeneous cells were pas-
saged as a single cell suspension using Accutase@ (Stem
Cell Technologies, Vancouver, Canada) with a 1:2 split ra-
tio. The cells were plated onto 0.1% gelatin-coated flasks
(passage 1 (P1)), and gelatin coating was only used for the
first two passages. After the P2 cells grew to be confluent,
they were passaged with MSC maintenance medium con-
taining high-glucose Dulbecco’s modified Eagle’s medium
(Hyclone, Logan, UT, USA), 10% fetal bovine serum (FBS;
Gibco, Grand Island, NY, USA), basic fibroblast growth
factor (5 ng/mL), and epidermal growth factor (10ng/mL).
After 3 to 4 passages, these cells appeared to be MSC-like.
The iPSC-MSCs at passage 10–15 were used for the func-
tion experiments. Human BM-MSCs were purchased from
Cyagen Biosciences Inc. (passage 2; Suzhou, JiangSu,
China). A total of eight batches of BM-MSCs from differ-
ent individuals served as controls.
Cell marker analysis of iPSC-MSCs
Cell surface markers and pluripotency markers were
analyzed for human iPSCs and iPSC-MSCs. We incu-
bated 1.5 × 105 cells with each of the following conju-
gated monoclonal antibodies: CD44-PerCP-Cy5.5,
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CD144-PerCP-Cy5.5, CD90-PE, CD73-PE, CD166-PE,
CD105-PE, CD34-APC, CD45-APC, OCT3/4-PE,
SOX-2-Percp-Cy5.5, TR-181-PE, and TRA-161-Percp-
Cy5.5 (BD Bioscience, San Diego, CA, USA), and ana-
lyzed with fluorescence-activated cell sorting (FACS).
For the analysis of the nuclear pluripotency markers
OCT3/4 and SOX-2, iPSCs were first ruptured by the
Transcription Factor Fixation/Permeabilization Con-
centrate Kit (eBioscience, USA), and then fluorescent
staining was performed. Nonspecific fluorescence was
determined by incubation of similar cell aliquots with
isotype-matched antibodies (BD Bioscience). Data were
analyzed using the Beckman Coulter Gallios flow cyt-
ometer (Fullerton, CA, USA). Analysis was performed
using FCS3.0 and Kaluza software (Beckman Coulter).
Reverse-transcription PCR analysis of SV40LT of U-iPSCs
and U-iPSC-MSCs
U-iPSCs were reprogrammed with plasmids containing
genes including SV40LT. SV40LT was evaluated in U-
iPSCs and in iPSC-MSCs at passage 4 using RT-PCR.
Total RNA was isolated using RNAiso Plus (Takara Bio,
Inc., Otsu, Japan) and cDNA was synthesized using the
PrimeScript™ RT Master Mix (TAKARA, Syuzou, Shiga,
Japan). The PCR reaction was performed; the PCR prod-
ucts were resolved on 1% agarose gel and were visualized
by ethidium bromide staining. The forward primers used
for PCR analysis are as follows: GAPDH (size 400 bp): for-
ward: 5′-CAAGGTCATCCATGACAACTTTG-3′; re-
verse: 5′-GTCCACCACCCTGTTGCTGTAG-3′. SV40LT
(size 491 bp): SV40T-SF1: 5′-TGGGGAGAAGAA
CATGGAAG-3′; IRES2-SR: 5′-AGGAACTGCTTCC
TTCACGA-3′.
In vitro tri-lineage differentiation assays
Osteogenesis
Briefly, differentiated iPSC-MSCs were seeded in gelatin-
coated six-well plates with 1 × 105 cells/well. Cells were
cultured in OriCell™ MSC osteogenic differentiation
medium (Cyagen Biosciences, Inc., Suzhou, China; Cat.
No. GUXMX-90021) for 28 days with media changes
twice a week. After 28 days of induction, osteogenesis
deposit formation was identified in the six-well plates
with the use of Alizarin Red staining (Alizarin Red S;
Sigma-Aldrich, Inc.). Images were taken using standard
light microscopy.
Adipogenesis
For adipogenic induction, iPSC-MSCs were seeded in
six-well plates at 1 × 105 cells per well. After the cells
reached 100% confluence, or postconfluency, the growth
medium was aspirated off and OriCell™ MSC adipogenic
differentiation basal medium A (Cat. GUXMX-90031;
Cyagen Biosciences, Inc.) was added. The medium was
completely replaced 3 days later by the adipogenic differ-
entiation basal medium B (Cat. GUXMX-90031; Cyagen
Biosciences, Inc., USA). One day later, the medium was
changed back to the induction medium. After three to
five cycles of induction/maintenance described above,
the cells were cultured in the maintenance medium for
an additional 7 days by replacing the medium every
3 days. Lipid deposits were observed after staining with
Oil Red (MP Biomedicals, Solon, OH, USA).
Chondrogenesis
Cell pellets from 2.5 × 105 iPSC-MSCs were centrifuged
at 600 g and cultured in polypropylene tubes in chon-
drogenic medium and the medium was changed three
times per week for 28 days. Pellet cultures were
formalin-fixed and paraffin embedded, sectioned, and
stained with Alcian blue (Sigma-Aldrich, Inc., USA).
Senescence β-galactosidase cell staining
To evaluate the senescence of MSCs, β-galactosidase
activity for BM-MSCs (passages 5, 8, and 11) and iPSC-
MSCs (passages 5, 8, 11, 17, and 50) was detected using
the senescence β-galactosidase cell staining kit (Cell Sig-
naling Technology, Beverly, MA, USA). In brief, cells
were seeded in six-well plates and fixed for 10–15 min
after cells reached 60–70% confluence. After washing,
the cells were incubated with β-galactosidase staining
solution at 37 °C for 16 h. Pictures for the positive stain-
ing of the blue color under an inverted microscope
(Leica, Wetzlar, Germany) were then taken. The mean
number of β-galactosidase-positive cells was calculated
from three fields chosen at random. There were three
replicates per condition.
Growth curve evaluation
The rate of growth of each cell line was calculated by
counting the total number of cells in duplicate wells
every day for 3 days.
Generation of monocyte-derived DCs
To obtain enough DCs, the buffy coats (which were by-
products of the separation of specific blood components
from healthy donors and provided by Guangzhou Blood
Center) were used for collecting human peripheral blood
mononuclear cells (PBMCs). A total of 38 samples from
healthy donors were used in our study. Buffy coats were
further separated by Ficoll-Paque PREMIUM density
gradient centrifugation (specific gravity, 1.078 g/mL;GE
Healthcare, England, UK). CD14+ monocytes were posi-
tively selected from PBMCs using the MACS CD14
MicroBeads (MiltenyiBiotec, Bergisch Gladbach, Germany).
We found that more than 89% of cells positively selected
using the MicroBeads were confirmed to be CD14+ mono-
cytes by FACS. The CD14+ monocytes were then cultured
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in RPMI 1640 medium supplemented with 10% FBS
(Gibco, Carlsbad, CA, USA), penicillin/streptomycin
(Gibco, Carlsbad, CA, USA), and recombinant granulocyte-
macrophage colony-stimulating factor (GM-CSF; 50 ng/
mL; PeproTech Inc., Rocky Hill, NJ, USA) and IL-4 (10 ng/
mL; R&D systems, Minneapolis, MN, USA). After 5 days,
cultured cells were harvested and analyzed by flow cytome-
try to assess the immature DCs (iDCs) phenotype (Fig. 2a).
CD14+ monocytes were stimulated with GM-CSF and IL-4
for 7 days but not with lipopolysaccharide (LPS) as the
control, and DCs are here referred to as iDCs day 7. DC
maturation was induced on day 5 by 100 ng/mL LPS
(Sigma-Aldrich, Inc., USA) stimulation for 2 additional days
(Fig. 3a). The anti-CD1a-APC, anti-CD14-PerCP-Cy5.5,
anti-CD80-PE, anti-CD83-PE-Cy5, anti-CD86-APC, anti-
HLA-DR-APC, and anti-CD40-PE from BD Biosciences
(San Diego, CA, USA) were used for cytofluorimetric
analysis for DC markers by triple- or double-color stain-
ing. Briefly, DCs were stained with the fluorochrome-
conjugated mAbs and incubated for 30 min at 4 °C. Each
isotype-match IgG was stained for equal cells as a control.
The cells were subjected to flow cytometry on a Beckman
Coulter Gallios equipped with Kaluza software (Fullerton,
CA, USA). The mean fluorescence intensity (MFI) was
calculated for the statistical analysis.
Co-culture of DCs and MSCs
Co-cultures were performed by plating the MSCs in six-
well plates overnight and co-cultured with CD14+
monocytes for 5 days (Fig. 2a). In addition, iDCs were
induced to mature on day 5 by LPS stimulation for 2
additional days in the presence or absence of MSCs
(Fig. 3a). On day 7, nonadherent DCs were harvested
and are referred to as iPSC-MSC-DCs. To investigate
the effects of iPSC-MSCs on DCs from the beginning of
the induction, CD14+ monocytes stimulated with GM-
CSF and IL-4 were co-cultured with iPSC-MSCs from
day 0 to day 7 and were stimulated by LPS from day 5
to day 7. These DCs are referred to as 7d-iPSC-MSC-
DCs. For the transwell culture experiments, a total of
5 × 105 CD14+ monocytes were seeded with a previously
plated iPSC-MSCs layer (5× 104 MSCs/well) in cell con-
tact or separately. iDCs were stimulated with LPS and
co-cultured with iPSC-MSCs in a transwell system from
day 5 to day 7 and then the DCs were harvested and are
referred to as iPSC-MSC-transwell-DCs. Co-culture DCs
and MSCs at ratios ranging from 1:10 to 1:100 were
used to determine an optimal co-culture condition.
Analysis of soluble factors and the application of the
inhibitors
To evaluate the soluble factors produced by iPSC-MSCs,
the monocytes were removed from the plates of co-
culture (on day 5) and then iPSC-MSCs were cultured
further in a fresh medium for an additional 24 h. Prosta-
glandin (PG)E2, IL-10, IL-6, and tumor necrosis factor-
stimulated gene 6 (TSG-6) levels were determined in the
supernatants of iPSC-MSCs cultured with or without
monocytes. To evaluate the cytokines produced by DCs,
DCs were collected from the co-cultures on day 7 and
then cultured in the new plates for an additional 12 h.
IL-10 or IL-12p70 levels were determined in the super-
natants of DCs cultured with or without iPSC-MSCs.
The factor levels were measured using an enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems,
Minneapolis, MN, USA).
To investigate the role of soluble factors on the immuno-
modulatory effects of iPSC-MSCs, the following reagents
were used for the co-culture systems: neutralizing anti-IL-6
(0.25 μg/mL; R&D Systems Europe, Abingdon, UK), anti-
IL-10 monoclonal antibody (0.075 μg/mL; R&D Systems
Europe), human recombinant IL-10 (0.5μg/mL; R&D
Systems Europe), or NS-398 (5 μM; Cayman Chemical,
Ann Arbor, MI, USA), an inhibitor of PGE2 synthesis.
Endocytosis assay
To compare the phagocytic ability of iDCs, mDCs, and
iPSC-MSC-DCs, cells were incubated for 1 h at 37 °C,
or at 4 °C as a negative control, with FITC-conjugated
dextran (Sigma-Aldrich, Inc.) at a final concentration of
100 μg/mL in RPMI 1640 containing 10% FBS. The cells
were then washed twice with ice-cold phosphate-
buffered saline (PBS) and resuspended in ice-cold PBS
for immediate analysis by flow cytometry.
Mixed lymphocyte reaction
In order to evaluate the effects of DCs under different
conditions on lymphocyte proliferation, mixed lympho-
cyte reactions between DCs and lymphocytes were per-
formed. After labeling with carboxyfluorescein diacetate
succinimidyl diester (CFSE) (Invitrogen/Molecular
Probes, Eugene, OR, USA) and suspension in RPMI
1640 supplemented with 10% FBS, allogeneic PBMCs
(5 × 105 cells/well) were cultured with mDCs (5 × 104
cells/well), iPSC-MSC-DCs (5 × 105 cells/well), or mDCs
(5 × 105 cells/well) under the transwell system (six-well
plates) with iPSC-MSCs, all of which were pre-treated
with mitomycin for 2 h (Sigma-Aldrich, Inc.). In some
experiments, the allogeneic PBMCs were treated by anti-
IL-10 antibody. After 3 days, cells were harvested and
analyzed by FACS.
Statistical analysis
Descriptive and analytical statistics were performed
using SPSS (version 15; Chicago, IL, USA) and graph-
prism software package. Descriptive data are presented
as the mean ± SD. Statistical analysis for comparison of
different groups was performed using the Student’s t test
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or analysis of variance (one-way ANOVA) where appro-
priate. Differences were considered statistically signifi-
cant when p values were less than 0.05.
Results
Characterization of human iPSC-derived MSCs
Using a modification of a previously described protocol
[13, 16], human MSCs were successfully generated from
two different iPSC clones reprogrammed from urine
cells (U-iPSC-MSCs), which were reprogramed by elec-
troporation with plasmids but not virus; the factors for
the reprogramming excluded oncogene c-MYC [28] and
amniocytes (A-iPSC-MSCs). Both U-iPSC-MSCs and A-
iPSC-MSCs exhibited a fibroblastic morphology, which
was similar to BM-MSCs (Fig. 1a). Unlike their parental
iPSCs, FACS showed that neither U-iPSC-MSCs nor A-
iPSC-MSCs expressed the reprograming factors Oct4,
Sox2, Klf4, or c-Myc. RT-PCR revealed that U-iPSCs,
but not U-iPSC-MSCs, showed expression of SV40LT,
another reprograming factor (Fig. 1b). Two iPSC-MSC
clones shared the same phenotype with BM-MSCs and
they were positive for CD105, CD73, CD90, CD146,
CD144, and CD44, and negative for CD34, CD14, and
CD45 at passage 4 (Fig. 1c) and passage 8 (data not
shown). Multi-potentiality of iPSC-MSCs was confirmed
using tri-lineage differentiation experiments including
osteogenic, chondrogenic, and adipogenic differentiation
(Fig. 1d). Moreover, similar results were confirmed using
P20 iPSC-MSCs (data not shown).
Interestingly, iPSC-MSCs exhibited a different growth
status compared to BM-MSCs. BM-MSCs were generally
passaged once every 3–4 days before passage 10 (P10),
grew slowly after P10, and almost lost the capability to
passage after P15. However, iPSC-MSCs were smaller,
grew faster, and were healthier. iPSC-MSCs were pas-
saged once every 2–3 days and almost kept the same
growth speed up to 50 passages or more. We evaluated
the aging of MSCs by detecting the β-galactosidase ac-
tivity (Fig. 1e and f). For BM-MSCs, the β-galactosidase
activity with blue staining was low at P5, moderate at
P8, and strong at P11. However, iPSC-MSCs exhibited
very low β-galactosidase activity at P5, P8, and P11
(Fig. 1e and f), and even P17 (Fig. 1e). Only some blue
staining was found for P50 iPSC-MSCs (Fig. 1e). In
addition, the growth curve showed that the growth vel-
ocity of iPSC-MSCs was higher than that of BM-MSCs
(Fig. 1g).
iPSC-MSCs inhibited the differentiation of CD14+
monocytes into DCs in a dose-dependent manner
In this study, CD14+ monocytes were induced to differ-
entiate to immature DCs with the stimulation of GM-
CSF and IL-4 for 5 days and were subsequently induced
to be mature with the addition for 2 days of LPS as
previously reported (Figs. 2a and 3a) [5]. We found that
the 5-day iDCs expressed the markers of immature DCs:
high CD1a (positive cells percentage: 74.51 ± 3.68%,
MFI: 732 ± 44), low CD14 (positive cells percentage:
16.89 ± 2.97%, MFI: 47 ± 7), and low levels of mature
markers of CD86 (MFI: 901 ± 134), HLA-DR (MFI:
1592 ± 142), CD40 (MFI: 30 ± 6), CD80 (MFI: 99 ± 10),
and CD83 (MFI: 49 ± 9) (Additional file 1: Figure S1).
Mature DCs with the additional stimulation of 2 days of
LPS showed higher levels of mature markers: CD86
(MFI: 1860 ± 187), HLA-DR (MFI: 2909 ± 133), and
CD40 (MFI: 54 ± 10), and especially for CD80 (MFI:
467 ± 71) and CD83 (MFI: 190 ± 41) (Additional file 1:
Figure S1). These results were consistent with previ-
ous studies [5, 23]. In addition, we tested the condi-
tions of DC differentiation of 7 days stimulation with
GM-CSF and IL-4. We found that the DCs (iDCs day
7) showed higher levels (MFI) of maturation marker
expressions (CD86 MFI: 935 ± 152, HLA-DR MFI:
2192 ± 136, CD40 MFI: 36 ± 8, CD80 MFI: 854 ± 86,
and CD83 MFI: 145 ± 18) compared to the iDCs
under the 5-day condition but much lower levels
compared to the mDCs (Additional file 1: Figure S1).
Therefore, we finally used the 5-day GM-CSF and IL-
4 stimulation as the condition for inducing immature
DCs, and 5-day GM-CSF and IL-4 plus 2 more days
of LPS as the condition for inducing mature DCs.
BM-MSCs have been reported to inhibit DC differenti-
ation from monocytes [4, 5, 23, 24]. We examined the
effects of iPSC-MSCs on the differentiation of DCs
(Fig. 2a). CD14+ monocytes became typical iDCs after a
5-day stimulation with GM-CSF and IL-4. They grew
thick dendrites and gathered into a mass. However, the
monocytes still kept the morphology of mononuclear
cells and were scattered around the iPSC-MSCs after
culture with iPSC-MSCs (Fig. 2b). In addition, co-
cultures of iPSC-MSCs or BM-MSCs and CD14+ mono-
cytes with ratios of 1:1, 1:5, and 1:10 clearly inhibited
differentiation of CD14+ monocytes into CD1a+ iDCs.
MSCs at a 1:10 MSC/monocyte ratio exhibited optimal
inhibition of CD1a and maintenance of CD14 (Add-
itional file 2: Figure S2A and B). Thus, co-culture with a
1:10 MSC/monocyte ratio was used in the subsequent
experiments.
After 5 days of co-culture, in the absence of MSCs,
monocytes differentiated into classic iDCs highly posi-
tive for CD1a and negative for CD14 and expressed
some levels of CD80, CD86, HLA-DR, CD83, and
CD40 (Fig. 2c and d; Additional file 1: Figure S1).
However, after co-culture with U-iPSC-MSCs and A-
iPSC-MSCs both at P8 and P18, monocytes displayed
a low expression of CD1a, but high expression of
CD14, and displayed low expression of CD80, HLA-
DR, CD83, and CD40. BM-MSCs showed a similar
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Fig. 1 Characterization of human induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs). a Morphology of iPSCs and iPSC-MSCs.
Urine cell-derived iPSCs (U-iPSCs) and amniocyte-derived iPSCs (A-iPSCs) were characterized by embryonic stem cell-like morphology, and iPSC-MSCs
from these clones of iPSCs had fibroblast-like morphology (original magnification, 100×). b Expression of the pluripotent markers OCT4, Sox-2, TRA-1-
60, and TRA-1-81 in U-iPSCs, A-iPSCs, U-iPSC-MSCs, and A-iPSC-MSCs by flow cytometry, and SV40LT DNA in U-iPSCs and U-iPSC-MSCs. Gray histograms
were negative isotypes. c Immunophenotype analysis of the MSC surface markers in U-iPSC-MSCs and A-iPSC-MSCs by flow cytometry.
Cells were harvested at passage 4. d Representative images of the differentiation of U-iPSC-MSCs toward adipogenic, osteogenic, and
chondrogenic lineages. e The representative pictures for the aging of U-iPSC-MSCs and bone marrow-derived MSCs (BM-MSCs) evaluated
by β-galactosidase activity. Arrows show the positive staining. f Statistical analysis for the β-galactosidase-positive cells of U-iPSC-MSCs and
BM-MSCs. Data are presented as mean ± SD. Three different batches of BM-MSCs were used. n = 3–5 replicates per condition. g Growth
curves for iPSC-MSCs and BM-MSCs. Three different batches of BM-MSCs were used. *P < 0.05, ***P < 0.001, versus BM-MSCs at the same
time point. nd not detectable, P passage
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Fig. 2 Induced pluripotent stem cell-mesenchymal stem cells (iPSC-MSCs) inhibited CD14+ monocytes differentiating into DCs. a CD14+ monocytes
were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 5 days to differentiate into immature
dendritic cells (iDCs) in the presence or absence of MSCs, and cell surface markers were examined by flow cytometry. b The morphology
of CD14+ monocytes (Mo) on day 0 (left), and in the presence of GM-CSF and IL-4 with (right) or without (middle) co-culture of urine
cell-derived induced pluripotent stem cell (U-iPSC)-MSCs on day 5. White arrows: iDCs; black arrows: U-iPSC-MSCs. c Representative experiment on the
expression of CD14, CD1a, CD86, CD80, HLA-DR, and CD83 on CD14+ monocytes (on day 0) or iDCs (day 5) with or without treatment with MSCs.
Phenotypic analysis was performed by gating on the leukocyte subset according to the forward scatter and side scatter. Numbers represent mean
fluorescence intensity. d Mean percentages of CD14- and CD1a-positive cells. Mean of the surface density of CD86, CD80, HLA-DR, and CD83 evaluated
as MFI (“cytofluorimetric analysis”). The results were obtained from six independent experiments. Three different batches of BM-MSCs were used. **P <
0.01, ***P < 0.001. A-iPSC amniocyte-derived induced pluripotent stem cell, BM bone marrow, P passage
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effect on CD1a and CD14 expression. Interestingly,
the monocytes kept high levels of CD80, HLA-DR,
and CD83 after co-culture with BM-MSCs and there
were significant differences in CD80, HLA-DR, and
CD83 levels between iPSC-MSCs and BM-MSCs
(Fig. 2d). These results indicate that iPSC-MSCs have
the potential to inhibit DC differentiation from
monocytes.
Fig. 3 Induced pluripotent stem cell-mesenchymal stem cells (iPSC-MSCs) had no effects on the phenotypic maturation of DCs. a CD14+ monocytes
were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 5 days to differentiate into immature dendritic
cells (iDCs). iDCs were further stimulated with lipopolysaccharide (LPS) for 2 days to mature into mature dendritic cells (mDCs), and treated with or without
MSCs. b The morphology of mDCs with or without co-culture with urine cell-derived induced pluripotent stem cell (U-iPSC)-MSCs. White arrows: mDCs;
black arrows: U-iPSC-MSCs. c The immunophenotype analysis of mDCs with or without treatment with MSCs by flow cytometry. One representative
experiment of six is shown. d The percentage of positive cells is shown for CD14 and CD1a, and the MFI is shown for CD86, CD40, CD80, HLA-DR, and
CD83. The data indicate the mean ± SD of six independent experiments. Three different batches of BM-MSCs were used. *P< 0.05. A-iPSC amniocyte-
derived induced pluripotent stem cell, BM bone marrow, P passage
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iPSC-MSCs did not affect phenotypic maturation of DCs
under LPS stimulation
We next investigated the effect of iPSC-MSCs on DC
maturation. LPS was added for 2 additional days starting
on day 5 to induce iDCs to become mDCs. The MSCs
were co-cultured with DCs from day 5 to day 7 (Fig. 3a).
DCs cultured without MSCs had many long and thick
dendrites and were scattered (Fig. 3b). However, DCs
displayed fewer and shorter dendrites and gathered
around iPSC-MSCs after co-culture with iPSC-MSCs.
Previous reports have shown that BM-MSCs inhibit DC
maturation [4, 23]. As expected, DCs acquired a typical
phenotype of mature DCs, including CD86, CD80,
HLA-DR, and CD83, after LPS stimulation (Fig. 3c and
d). The expression of CD86 significantly decreased after
DCs were co-cultured with BM-MSCs. However, there
were no significant differences in the surface density of
the co-stimulatory molecules CD86 and HLA-DR in
DCs cultured in the presence of two clones of iPSC-
MSCs (at both P8 and P18). It was a little surprising that
higher levels of CD80 and CD83 were observed in DCs
cultured with iPSC-MSCs compared with those of
mDCs cultured alone or with BM-MSCs. Our findings
indicate that iPSC-MSCs did not affect iDCs to become
mDCs. In addition, BM-MSCs had no effect on the ex-
pression of CD80, HLA-DR, and CD83 in mDCs.
As shown in Additional file 1 (Figure S1), iDCs
showed low expression of mature markers of DCs, iDCs
day 7 showed some expression, and mDCs showed high
expression of mature markers of DCs. iPSC-MSCs de-
creased the expression of mature markers in iDCs
(Fig. 2c and d) but they did not exhibit the inhibition on
mature markers in mDCs (Fig. 3c and d). Therefore, we
further examined the effects of iPSC-MSCs on mature
marker expression in iDCs day 7 which showed some
expression of mature markers. The results showed that
iDCs day 7 had some levels of maturation marker ex-
pressions, including CD80, HLA-DR, CD40, and CD83
(Additional file 1: Figure S1 and Additional file 3: Figure
S3). However, there were no significant differences in
DC mature markers between iPSC-MSC-DCs and iDCs
day 7 (Additional file 3: Figure S3). Although we ob-
served that iPSC-MSCs inhibited the expression of some
mature markers with low levels in iDCs, iPSC-MSCs did
not exhibit any inhibition on mature marker expression
in the mDCs with high levels of mature expression. Our
data suggest that iPSC-MSCs did not affect iDCs to be-
come mDCs.
iPSC-MSCs induced IL-10-producing DCs in the progress
of LPS-induced DC maturation
We next examined the effects of iPSC-MSCs on mDC
function. The mDCs, iPSC-MSC-DCs (Fig. 4a), and 7d-
iPSC-MSC-DCs were prepared. Firstly, we studied the
lymphocyte-stimulating ability of iPSC-MSC-DCs using
a mixed lymphocyte culture (MLC) system. As expected,
mDCs displayed stronger lymphocyte-stimulating cap-
ability (Fig. 4a and b). However, iPSC-MSC-DCs com-
pletely lost their ability to stimulate lymphocyte
proliferation compared to mDCs. Several studies have
reported that adult MSCs are capable of inducing the
generation of regulatory DCs during DC maturation
[25–27]. We therefore examined the phagocytic capacity
of iPSC-MSC-DCs. The results showed that iPSC-MSC-
DCs had stronger phagocytic capacity compared to
mDCs (Fig. 4c and d), suggesting that iPSC-MSC-DCs
may have a capability of immune tolerance similar to
iDCs.
Generally, IL-10 levels represent the function of
regulatory DCs whereas IL-12 levels represent the
pro-inflammatory capacity. Higher levels of IL-10
were observed in iPSC-MSC-DCs compared to mDCs
(Fig. 4e) suggesting that iPSC-MSC-DCs may have a
stronger immunomodulatory function similar to regu-
latory DCs. A puzzling observation was that there
were higher levels of IL-12p70 in iPSC-MSC-DCs
compared to mDCs (Fig. 4f ). This finding may sug-
gest that the modulation of DCs by iPSC-MSCs is
complex and some parameters may have different re-
sponses. Moreover, 7d-iPSC-MSC-DCs, which were
DCs co-cultured with iPSC-MSCs for 7 days, pro-
duced less IL-10 and IL-12p70 (Fig. 4e and f ), sug-
gesting that iPSC-MSCs inhibit DC function at the
beginning of differentiation.
Previous studies have shown that regulatory DCs in-
hibit, rather than promote, lymphocyte proliferation.
Here, iPSC-MSC-DCs were further co-cultured with
mDCs and allogenic PBMCs for 3 days. Unlike mDCs
(Fig. 5a and b), iPSC-MSC-DCs significantly inhibited
lymphocyte proliferation stimulated by both mDCs
(Fig. 5a and b) and anti-CD3/CD28 (data not shown).
Taken together, these results demonstrate that iPSC-
MSCs induce the generation of IL-10-producing regulatory
DCs during LPS-induced DCs maturation.
Cell-cell contact and IL-10 were responsible for the iPSC-
MSC-mediated inhibition of DC differentiation
To identify the mechanism of the inhibition of DC dif-
ferentiation by iPSC-MSCs, we examined the role of
cell-to-cell contact and some soluble factors. The inhibi-
tory effects of iPSC-MSCs (Fig. 6a) on the high CD1a
expression in monocytes induced by GM-CSF and IL-4
(Fig. 6a) almost disappeared in the transwell system
(Fig. 6a and b). However, CD14 expression was not dif-
ferent in the transwell system. Interestingly, we found
that CD14+ monocytes cultured with the supernatant of
iPSC-MSCs exhibited similar inhibitory effects on high
levels of CD1a, with no effects on CD14 expression
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(Fig. 6a and c). These findings indicate that iPSC-MSCs
might exert their inhibitory effects on DC differentiation
via both cell-cell contact and soluble factors.
Several soluble factors have been reported to contrib-
ute to the immunomodulatory effects of MSCs, and the
roles of PGE2, IL-10, IL-6, and TSG-6 have been espe-
cially well established. We have previously reported that
suppression of T-cell proliferation by iPSC-MSCs was
mediated by both the production of PGE2 and cell-cell
contact [18]. Here, we investigated the role of these fac-
tors on iPSC-MSC-mediated inhibition on DC differenti-
ation. There were low levels of IL-10 in the supernatant
of iPSC-MSCs (Fig. 6d) or CD14+ monocytes (data not
shown) cultured alone. iPSC-MSCs were separated from
the co-culture system with DCs and cultured further in
a fresh medium for an additional 24 h. Then the super-
natant was collected for the examination of IL-10 levels.
After co-culture with DCs, IL-10 levels produced by
Fig. 4 Induced pluripotent stem cell-mesenchymal stem cells (iPSC-MSCs) induced the generation of IL-10-producting DCs under LPS stimulation.
Allogenic peripheral blood mononuclear cells (PBMCs) were stained with carboxyfluorescein diacetate succinimidyl diester (CFSE) and co-cultured
for 72 h with mature dendritic cells (mDCs) or iPSC-MSC-DCs, and lymphocyte proliferation was assessed by flow cytometry. a Representative ex-
periments assessing lymphocyte proliferation. b The effects of iPSC-MSCs on the function of mDCs in lymphocyte proliferation. c Phagocytic abil-
ity of the DCs was analyzed by flow cytometry. d Statistical analysis of the phagocytic ability of DCs (the mean fluorescence intensity (MFI) of
dextran). e Interleukin-10 (IL-10) and f IL-12p70 levels produced by mDCs, iPSC-MSC-DCs, or 7d-iPSC-MSC-DCs. The findings were confirmed using
U-iPSC-MSCs and A-iPSC-MSCs and the data represent the means ± SD of six independent experiments using U-iPSC-MSCs. *P < 0.05, **P < 0.01,
***P < 0.001. FITC fluorescein isothiocyanate, iDCs immature DCs, iPSC-MSC-DCs DCs co-cultured with iPSC-MSCs from day 5 to day 7 in the pres-
ence of GM-CSF, IL-4, and LPS, 7d-iPSC-MSC-DCs DCs co-cultured with iPSC-MSCs from day 0 to day 7 under conditions of general DC culture in
Figs. 2a and 3a
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iPSC-MSCs dramatically increased seven-fold (98.7 ±
1.01 pg/mL vs 13.8 ± 0.52 pg/mL) after 1 day, and 10-
fold (150.3 ± 11.63 pg/mL vs 13.8 ± 0.52 pg/mL) after
5 days (Fig. 6d). To further confirm the production of
IL-10 from iPSC-MSCs, we performed IL-10 immuno-
staining on iPSC-MSCs. There was no positive IL-10
staining in iPSC-MSCs cultured alone (Additional file 4:
Figure S4C). However, strong IL-10 staining was ob-
served in iPSC-MSCs after culture with monocytes on
day 5 (Additional file 4: Figure S4D). No significant dif-
ferences were found in PGE2 (1526 ± 248 pg/mL vs
1721 ± 161 pg/mL) (Fig. 6e), IL-6, or TSG-6 levels in the
supernatants between iPSC-MSCs cultured with iDCs
and those without iDCs (data not shown). In addition,
there were no significant differences in PGE2, IL-10, IL-
6, and TSG-6 levels in the supernatants of iDCs with or
without iPSC-MSCs (data not shown).
We next investigated whether blocking IL-10 function
reversed the inhibition of monocyte differentiation into
DCs by iPSC-MSCs. No IL-10 could be detected after
the administration of IL-10 neutralizing antibody. IL-10
neutralizing antibody dramatically reversed the high
CD14 level (82.3 ± 6.5%) induced by iPSC-MSCs to a
low level (24.7 ± 3.3%), and reversed the low CD1a level
(20.7 ± 2.8%) induced by iPSC-MSCs to a high level
(53.5 ± 4.6%) (Fig. 6a and c). This finding suggests that
IL-10 plays a major role in the iPSC-MSC-mediated in-
hibition of DC differentiation. Moreover, similar to
iPSC-MSCs, the recombinant IL-10 significantly inhib-
ited the CD1a expression but was still weaker than those
of the treatment of iPSC-MSCs (Fig. 6a and c). Recom-
binant IL-10 also increased CD14 levels to similar levels
as iPSC-MSCs (Fig. 6a and c). In addition, the administra-
tion of NS-398, a specific inhibitor of PGE2 synthesis,
significantly reversed the effects of iPSC-MSCs on CD14,
but not CD1a expression (Fig. 6a and c). Taken together,
these data suggest that both cell-cell contact and soluble
factors, especially IL-10, are responsible for the iPSC-
MSC-mediated inhibition of DC differentiation.
Cell-cell contact contributed to the induction of IL-10-
producing DCs by iPSC-MSCs
We next investigated the mechanisms by which iPSC-
MSCs induced the generation of regulatory DCs. The
DCs co-cultured with iPSC-MSCs in a transwell system
(iPSC-MSC-DCs + Transwell) were collected and co-
cultured with allogenic PBMCs or with the co-culture
system of mDCs and allogenic PBMCs (Fig. 7a), and
lymphocyte proliferation was assessed. iPSC-MSC-DCs
significantly inhibited lymphocyte proliferation stimu-
lated by mDCs. However, the transwell system signifi-
cantly reversed the inhibition of iPSC-MSC-DCs on
lymphocyte proliferation stimulated by mDCs, resulting
in a high proliferation rate (Fig. 7). Anti-IL-10 monoclo-
nal antibody, as well as NS-398 and anti-IL-6 antibody
(data not shown), did not affect the effects of iPSC-
MSC-DCs on lymphocyte proliferation (Fig. 7). These
results indicate that iPSC-MSCs might induce regulatory
DCs primarily through cell-cell contact.
Discussion
The immunomodulatory properties of MSCs have been
well characterized and used for the treatment of several
immune diseases, such as graft-versus-host disease
(GVHD) [30]. Despite the availability of MSCs from
adult/newborn tissue such as BM [31], these cells have a
limited proliferative capacity, a large variability in cell
quality derived from different donors, and quickly lose
Fig. 5 iPSC-MSC-DCs inhibited the effects of mature dendritic cells (mDCs) on peripheral blood mononuclear cell (PBMC) proliferation. a
Representative experiments assessing lymphocyte proliferation. b The effects of iPSC-MSC-DCs on the function of mDCs in lymphocyte proliferation.
The findings were confirmed using U-iPSC-MSCs and A-iPSC-MSCs and the data represent the means ± SD of six independent experiments using U-
iPSC-MSCs. *P < 0.05. CFSE carboxyfluorescein diacetate succinimidyl diester, iPSC-MSC-DCs dendritic cells co-cultured with induced pluripotent stem
cell-mesenchymal stem cells from day 5 to day 7 in the presence of GM-CSF, IL-4, and LPS.
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Fig. 6 Interleukin-10 (IL-10) was responsible for the inhibition of DC differentiation by induced pluripotent stem cell-mesenchymal stem cells
(iPSC-MSCs). Immature dendritic cells (iDCs) were prepared as in Fig. 2a in the absence (a, top row second panel) or in the presence (a, top row
third panel) of iPSC-MSCs or using a transwell chamber system (a, top row fourth panel) to separate the monocytes (Mo) and iPSC-MSCs, or with
the administration of the supernatant of cultured iPSC-MSCs (a, bottom row first panel). In addition, anti-IL-10 antibody (a, bottom row second
panel) or the PGE2 synthesis inhibitor NS-398 (a, bottom row fourth panel) was added to monocyte-iPSC-MSCs co-cultures. Recombinant IL-10
(rhIL-10) was administered to the iDC culture system (a, bottom row third panel). After 5 days, DCs were harvested and phenotypic analysis was
performed. a A representative experiment showing the percentage of CD14- or CD1a-positive cells. b The role of cell-cell contact involved in the
effects of iPSC-MSCs on DC differentiation (statistical analysis for the expression of CD14 and CD1a in monocytes or DCs). c The role of soluble
factors involved in the effects of iPSC-MSCs on DC differentiation (statistical analysis of the expression of CD14 and CD1a in monocytes or DCs). d
IL-10 levels in the culture supernatant of iPSC-MSCs co-cultured with CD14+ monocytes in the presence of GM-CSF and IL-4 for 0, 1, and 5 days.
e Prostaglandin E2 (PGE2) levels in the supernatants between iPSC-MSCs cultured with or without iDCs. Our findings were confirmed using U-
iPSC-MSCs and A-iPSC-MSCs. The results are expressed as the mean ± SD of the percentages of marker-positive cells obtained from the analysis of
six independent experiments using U-iPSC-MSCs. **P < 0.01, ***P < 0.001. N.S not significant
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their differentiation potential [32]. All of these factors
limit their therapeutic benefit, especially for clinical ap-
plications [6, 7, 33, 34]. Recently, much interest has been
generated in the induction of iPSCs to differentiate into
MSCs, and iPSC-MSCs displayed a higher proliferation
rate [35]. More importantly, we have recently reported
that, compared to BM-MSCs, human iPSC-MSCs are
less immunogenic and have a stronger immune privilege
after transplantation [14]. These findings indicate that
iPSC-MSCs may be a source of more easily derived and
acceptable MSCs, especially for clinical applications. To
date, the iPSCs used for the generation of MSCs were
mostly reprogrammed using a virus-based approach, thus
raising safety concerns that may limit their further appli-
cation. In this study, MSCs were successfully induced
from two different iPSC clones and expressed well-known
adult BM-MSC markers, displayed the potential for adipo-
genesis, osteogenesis, and chondrogenesis, and had higher
capacity for proliferation. Furthermore, in our study, U-
iPSC-MSCs were derived from U-iPSCs which were re-
programed by electroporation with plasmids but not virus,
cultured in animal serum- and feeder-free medium, and
the factors for the reprogramming excluded the oncogene
c-MYC [28]. More importantly, we found that iPSC-MSCs
at passage 5 to passage 18 did not exhibit any cell senes-
cence, and displayed some aging only at passage 50. How-
ever, BM-MSCs exhibited clear aging at passage 8,
displayed cell senescence in almost all of the cells at pas-
sage 11, and generally lost the capability to passage above
passage 11. Our results show that iPSC-MSCs at both
passage 8 and 18 had similar immunomodulatory
effects on DC differentiation and functions as BM-
MSCs at passage 5, suggesting a promising applica-
tion potential for immunotherapy. Of course, we
acknowledge our limitation that here we did not pro-
vide safety data, for example using immunodeficiency
mice. In our previous study, we found that two clones
of iPSC-MSCs significantly prevented allergic airway
inflammation [19], and the iPSC-MSCs were con-
firmed not to induce any tumor formation in the
4 months after their subcutaneous transplantation
into severe combined immunodeficient mice [12].
Fig. 7 Cell-cell contact was the main mechanism responsible for the generation of interleukin-10 (IL-10)-producing DCs with the treatment of
iPSC-MSCs. iPSC-MSC-DCs were prepared as in Fig. 3a. a Representative experiments assessing lymphocyte proliferation. b The role of cell-cell
contact and soluble factors on the effects of iPSC-MSCs on the function of mature dendritic cells (mDCs) in lymphocyte proliferation. The findings
were confirmed using U-iPSC-MSCs and A-iPSC-MSCs and the data represent the means ± SD of six independent experiments using U-iPSC-MSCs.
***P < 0.001. Anti-IL-10 anti-IL-10 neutralizing antibody, CFSE carboxyfluorescein diacetate succinimidyl diester, iPSC-MSC-DCs dendritic cells co-
cultured with induced pluripotent stem cell-mesenchymal stem cells from day 5 to day 7 in the presence of GM-CSF, IL-4, and LPS, PBMC peripheral
blood mononuclear cell
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Previous reports have shown a potent inhibitory effect
of MSCs on DC differentiation and function [4, 5, 24,
25, 36, 37]. As the most potent antigen-presenting cells,
DCs are believed to be the most important cells involved
in many immune diseases including asthma. Our previ-
ous study [19] demonstrating that iPSC-MSC adminis-
tration, not only before the challenge but also before the
sensitization, prevented allergic airway inflammation also
indicates that iPSC-MSCs may regulate DC function
since DCs were the major immune cells involved in the
process of sensitization of allergic disease. In the present
study, we identified that iPSC-MSCs exerted an import-
ant inhibitory effect on DC differentiation both by pro-
ducing IL-10 and by direct cell contact, and induced the
generation of an IL-10-producing regulatory DC subset
in the progress of LPS-induced maturation mostly by a
cell-cell contact mechanism. We previously reported that
iMR90-iPSC-MSCs and N1-iPSC-MSCs prevented allergic
airway inflammation [19]. In our study, we induced 2–4
clones derived from the U-iPSCs and A-iPSCs and we
confirmed our results for iMR90-iPSC-MSCs, N1-iPSC-
MSCs, and the other clones of U-iPSC-MSCs and A-
iPSC-MSCs (data not shown). Together, these results
indicate that iPSC-MSCs play an important role in the
treatment of DC-mediated diseases, such as allergic
asthma and allergic rhinitis.
Previous studies [4, 5, 24–26, 37] have reported almost
consistent findings that MSCs inhibited the differenti-
ation of DCs, but they showed varied results for MSCs
on monocyte-DC maturation, such as inhibitory effects,
no effects, or induction of regulatory DC. Here, we show
that iPSC-MSCs inhibited differentiation of CD14+
monocytes into DCs at the early stages of the differenti-
ation process, which was consistent with previous re-
ports in BM-MSCs [4, 5]. Furthermore, after the
administration of iPSC-MSCs during DC maturation,
the DCs still acquired the mDC phenotype of CD80,
CD86, CD83, and HLA-DR, but displayed high phago-
cytic ability, impaired T-cell stimulatory capacity, pro-
duction of IL-10, and inhibitory activity on T-cell
proliferation. This finding suggests that human iPSC-
MSCs affect the function of mDCs by inducing mDCs to
acquire some immunomodulatory properties of regula-
tory DCs. This suggestion is consistent with previous
studies [25, 26, 37, 38], which demonstrated that mouse
or human MSCs induced the generation of regulatory
DCs. Because of the important functions of the regula-
tory DCs in the induction of tolerance [39], our results
indicate that iPSC-MSCs might be able to suppress aller-
gic inflammation via the induction of regulatory DCs.
BM-MSCs were reported to decrease the expression of
CD markers [4] or to have no effects [5] in the progress
of DC maturation. In this study, we found that iPSC-
MSC treatment during DC maturation did not affect the
expression of HLA-DR and CD86, suggesting a different
mechanism underlying the effect between iPSC-MSCs
and BM-MSCs on DC maturation. However, it was a lit-
tle surprising that iPSC-MSCs increased the expression
of CD80 and CD83 on DCs. Despite exhibiting similar
binding affinity to the CD28 ligand, CD80 and CD86 ex-
hibit different biochemical characteristics that can result
in different T-cell functional outcomes [40]. The poten-
tial significance of the effects of iPSC-MSCs on CD
markers is very interesting and should be further studied
in the future. Our data at least indicate that iPSC-MSCs
did not affect iDCs to become mDCs.
Our study indicates that iPSC-MSCs exert different
immunomodulatory effects on DCs in different stages of
DC development. This suggestion is consistent with the
reports that MSCs display different regulatory functions
under different conditions. A series of studies strongly
support the notion that immunoregulatory function of
MSCs is highly plastic [30] and is dependent upon their
microenvironment. For example, MSCs exerted immu-
nomodulation in both GVHD (a Th1-dominated disease)
and asthma (a Th2-dominated disease) [30].
Previous studies have reported that adult MSCs
exerted different effects on DCs: BM-MSCs decrease DC
markers [5] but cord blood-derived MSCs have no ef-
fects during DC differentiation [36]. In our study, we
also observed that iPSC-MSCs exerted different effects
on DC differentiation compared to BM-MSCs. Unlike
iPSC-MSCs, BM-MSCs decreased the expression of
CD86 and CD40, but not CD80, HLA-DR, and CD83.
The different origin of MSCs may explain these different
results, suggesting that MSCs of different origin may dis-
play different functional properties. Furthermore, iPSC-
MSCs and BM-MSCs also exhibited different effects on
DC markers in the DC maturation. Our findings in simi-
lar culture conditions indicate that iPSC-MSCs exert
different effects or even stronger inhibition of
monocyte-derived DC differentiation compared to BM-
MSCs. Our previous studies have shown that iPSC-
MSCs have immunomodulatory properties similar to
BM-MSCs but also display some differences compared
to BM-MSCs, such as low HLA-DR expression stimu-
lated by inflammation [14]. Together, these findings in-
dicate that iPSC-MSCs may have more advantages in
therapeutic applications in the future.
Cell-cell contact and paracrine factors have been re-
ported to be the major mechanisms underlying the ef-
fects of MSCs on DCs. We found that both soluble
factors, especially IL-10, and cell-cell contact were in-
volved in the differentiation stage, whereas cell-cell con-
tact was the primary mechanisms during the maturation
stage. Moreover, IL-10 was the main factor responsible
for the inhibition of CD1a induction, and cell-cell con-
tact was mainly involved in the maintenance of high
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CD14 expression, suggesting that different mechanisms
or signaling pathways are involved in the effects of iPSC-
MSCs on different cellular markers of DCs. Further-
more, we found that iPSC-MSCs regulated the function
of DCs in the process of maturation by inducing the
generation of regulatory DCs mainly through cell-cell
contact. A previous study has shown that Fas/FasL, an
important signaling pathway in apoptosis, was involved
in the cell-cell contact mechanism of MSC immunomo-
dulation [41], and has been reported to enhance the im-
munosuppressive function of regulatory DCs [42]. In
this study, we found that there were no differences in
Fas and FasL mRNA and protein levels in DCs in the
presence or absence of iPSC-MSCs (data not shown),
suggesting that the regulatory DCs induced by iPSC-
MSCs at least do not exert their inhibitory function
through the Fas/FasL signaling pathway.
Conclusions
In conclusion, we successfully induced MSCs from two
clones of human iPSCs. We demonstrated the immuno-
modulatory effects of iPSC-MSCs, even at passage 18,
on the differentiation and function of monocyte-derived
DCs and the possible mechanisms of these effects.
Moreover, we found that iPSC-MSCs induced the gener-
ation of regulatory DCs in the process of DC matur-
ation. Our study indicates that pluripotent stem cell-
derived MSCs can serve as an alternative to adult MSCs
for the treatment of immune diseases targeting DCs in
the future.
Additional files
Additional file 1: Figure S1. The levels of mature markers in DCs with
different conditions. iDCs: CD14+ monocytes were stimulated with GM-CSF
and IL-4 for 5 days. iDCs day 7: CD14+ monocytes were stimulated with GM-
CSF and IL-4 for 5 days. mDCs: CD14+ monocytes were stimulated with GM-
CSF and IL-4 for 7 days and were stimulated by lipopolysaccharide (LPS) from
day 5 to day 7. *P< 0.05, **P < 0.01. iDCs immature DCs, mDCs mature DCs,
GM-CSF granulocyte-macrophage colony-stimulating factor. (TIF 3189 kb)
Additional file 2: Figure S2. MSCs inhibited the differentiation of DCs
from CD14+ monocytes in a dose-dependent manner. CD14 and CD1a
expression of CD14+ monocyte-derived cells in MSC/monocyte co-cultures
at ratios ranging from 1:1 to 1:100 was assessed by flow cytometry. The
results are representative of three independent experiments using (A) U-
iPSC-MSCs and (B) BM-MSCs. Three different batches of BM-MSCs were used.
CD14+ Mo CD14+ monocytes, iDCs immature DCs. (TIF 3434 kb)
Additional file 3: Figure S3. iPSC-MSCs did not affect iDC day 7
maturation. CD14+ monocytes cultured in the presence of GM-CSF
and IL-4 for 7 days. iPSC-MSC-DCs without LPS: iDCs cultured with
iPSC-MSCs in the presence of GM-CSF and IL-4 without additional
LPS stimulation. The immunophenotype analysis of iPSC-MSC-DCs
without LPS and iDCs day7 by flow cytometry. One representative
experiment (U-iPSC-MSCs) of six is shown. iDCs immature DCs, GM-
CSF granulocyte-macrophage colony-stimulating factor. (TIF 795 kb)
Additional file 4: Figure S4. IL-10 expression in iPSC-MSCs after culture
with DCs. IL-10 immunofluorescence images in U-iPSC-MSCs cultured
alone (A,B) or with CD14+ monocyte cells for 5 days (D–F). (A) Bright field
image for U-iPSC-MSCs cultured only. (B) Bright field image for U-iPSC-
MSCs co-cultured with iDCs for 5 days. (C) IL-10 immunofluorescent staining
in U-iPSC-MSCs cultured alone. (D) IL-10 immunofluorescent staining in U-
iPSC-MSCs after separation from iPSC-MSCs/iDC co-culture system. Blue
represents DAPI staining of nuclei and red represents IL-10 staining.
Images are representative of three separate experiments. Scale bar =
50 μm. CD14+ Mo CD14+ monocytes, iDCs immature DCs, DAPI 4′,6-
diamidino-2-phenylindole dihydrochloride. (TIF 7436 kb)
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